The clinically used photosensitizer Verteporfin (VP) inhibits YAP-TEAD and human retinoblastoma cell growth in vitro without light activation
- 15 May 2014
- journal article
- Published by Elsevier BV in Experimental Eye Research
- Vol. 124, 67-73
- https://doi.org/10.1016/j.exer.2014.04.011
Abstract
No abstract availableKeywords
This publication has 60 references indexed in Scilit:
- Aminoimidazole Carboxamide Ribonucleotide (AICAR) Inhibits the Growth of Retinoblastoma In Vivo by Decreasing Angiogenesis and Inducing ApoptosisPLOS ONE, 2013
- Regulation of the Hippo–YAP pathway by protease-activated receptors (PARs)Genes & Development, 2012
- Genetic and pharmacological disruption of the TEAD–YAP complex suppresses the oncogenic activity of YAPGenes & Development, 2012
- Oncogenic YAP promotes radioresistance and genomic instability in medulloblastoma through IGF2-mediated Akt activationOncogene, 2011
- Photodynamic therapy of cancer: An updateCA: A Cancer Journal for Clinicians, 2011
- AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinomaOncogene, 2010
- Retinoblastoma cells are inhibited by aminoimidazole carboxamide ribonucleotide (AICAR) partially through activation of AMP‐dependent kinaseThe FASEB Journal, 2010
- Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-β-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapyMolecular Cancer, 2007
- Initiation of apoptosis and autophagy by photodynamic therapyLasers in Surgery and Medicine, 2006
- The role of autophagy in cancer development and response to therapyNature Reviews Cancer, 2005